Pancreatic cancer is an aggressive form of cancer that carries only a 7% survival rate at five years after the initial diagnosis. It is one of the largest causes of cancer-related death. Although there are options available for treating pancreatic cancer, they are only associated with an average survival of less than one year. This, in part, has to do with the absence of obvious signs and symptoms during the early stages of pancreatic cancer. By the time it is diagnosed, cancer has often already spread (or metastasized) to other parts of the body. The poor prognosis and low survival outcomes stress the need for new therapeutic targets for treating pancreatic cancer. Read more . . .
A molecule produced by tumour cells, known as perlecan, may be the key for targeting and treating pancreatic cancer.